TILT Biotherapeutics is the world’s leading company developing oncolytic immunotherapies to enable T-cell therapy of solid tumors. It is headquartered in Finland (TILT Biotherapeutics Oy) with a fully owned subsidiary in the United States (TILT Biotherapeutics LLC).
Tiltbio’s Origins
The company’s origins can be traced to an article on oncolytic viruses that Tiltbio’s founder and CEO Akseli Hemminki, M.D., Ph.D. read in the late 1990s. Dr. Hemminki’s recognized that the potential of oncolytic viruses matched his desire to directly help people living with cancer. This led him to continue his education, conducting post-doctoral research in the United States on oncolytic viruses.
Dr. Hemminki then returned to the University of Helsinki in 1999 as a Resident in Oncology and Radiology. He was named Professor of Oncology in 2007 and ran a compassionate treatment program from 2007 to 2012 that treated 290 patients with 10 different oncolytic viruses.
Dr. Hemminki’s research team used patient observations and proof of concept data from these patients to confirm the pivotal role of immunity in combating cancer with oncolytic virus therapies.
TILT Biotherapeutics is Born
This significant insight led to the creation of TILT Biotherapeutics in 2013 and its pioneering, patented TILT® technology.
Since its inception, the company has carried its lead oncolytic immunotherapy candidate TILT-123 through Phase I trials with patients from around the world. The company’s leading program, TILT-123 for ovarian cancer in combination with immune checkpoint inhibition, is now in Phase II clinical development in the U.S. Other clinical Phase Ib trials with TILT-123 in combination with cancer immunotherapies in Europe and the U.S. continue also for solid tumors, such as melanoma, lung and head & neck cancers.
Looking to the Future
Tiltbio is building a pipeline of investigational cancer immunotherapies intended to treat solid tumors, with ovarian cancer as the lead indication.
Tiltbio is open to collaborations with pharmaceutical companies, specifically in the context of enhancing the therapeutic efficacy of cancer immunotherapies in development by stimulating T cells.
Tiltbio is also looking to explore licensing agreements to support the commercialization of its pipeline.
Our Mission, Vision, and Values:
Mission: To invest in a new future in cancer treatment by developing cutting-edge oncolytic viral technologies that activate the immune system, offering hope to patients with limited treatment options.
Vision: A future where cancer patients have access to innovative, life-saving therapies, so they can live longer and live better.
Values:
- Investment in patients: Our commitment to delivering new therapies to patients in need drives everything we do.
- Interconnected success: We believe in the power of teamwork and shared knowledge to achieve our goals.
- Integrity: We uphold the highest ethical standards in our work and take responsibility for delivering on our promises to patients and the scientific community.
- Impact: We aim to continually push the limits of what’s possible and are dedicated to making a real difference in the fight against cancer.